
Samuel W Brady

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11467102/publications.pdf Version: 2024-02-01



SAMILEL W/ RDADY

#	Article	IF	CITATIONS
1	Therapeutic and prognostic insights from the analysis of cancer mutational signatures. Trends in Genetics, 2022, 38, 194-208.	6.7	39
2	A`one-two punch' therapy strategy to target chemoresistance in estrogen receptor positive breast cancer. Translational Oncology, 2021, 14, 100946.	3.7	8
3	Exploration of Coding and Non-coding Variants in Cancer Using GenomePaint. Cancer Cell, 2021, 39, 83-95.e4.	16.8	18
4	The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms. Nature Communications, 2021, 12, 985.	12.8	31
5	Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy. Blood Cancer Discovery, 2021, 2, 326-337.	5.0	71
6	Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing. Cancer Discovery, 2021, 11, 3008-3027.	9.4	88
7	Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse. Nature Cancer, 2021, 2, 819-834.	13.2	24
8	St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem. Cancer Discovery, 2021, 11, 1082-1099.	9.4	109
9	The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. Nature Communications, 2021, 12, 6468.	12.8	35
10	The landscape of coding RNA editing events in pediatric cancer. BMC Cancer, 2021, 21, 1233.	2.6	7
11	Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations. Nature Communications, 2020, 11, 5183.	12.8	87
12	Therapy-induced mutagenesis in relapsed ALL is supported by mutational signature analysis. Blood, 2020, 136, 2235-2237.	1.4	1
13	Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood, 2020, 135, 41-55.	1.4	171
14	The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment. Molecular Cancer Research, 2019, 17, 895-906.	3.4	40
15	Combating subclonal evolution of resistant cancer phenotypes. Nature Communications, 2017, 8, 1231.	12.8	124
16	Targeting Aberrant p70S6K Activation for Estrogen Receptor–Negative Breast Cancer Prevention. Cancer Prevention Research, 2017, 10, 641-650.	1.5	4
17	HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Molecular Oncology, 2015, 9, 586-600.	4.6	31
18	PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition. Cancer Biology and Therapy, 2015, 16, 402-411.	3.4	44

SAMUEL W BRADY

#	Article	IF	CITATIONS
19	Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer. Cancer Research, 2015, 75, 4863-4875.	0.9	44
20	Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. Cell Research, 2014, 24, 542-559.	12.0	23
21	Enhanced PI3K p110α Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110α-Selective PI3K Inhibitor. Molecular Cancer Therapeutics, 2014, 13, 60-70.	4.1	34
22	Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer. Cancer Research, 2012, 72, 4417-4428.	0.9	42
23	Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nature Medicine, 2011, 17, 461-469.	30.7	466